

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2023 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 13 OCTOBER 2023

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) is pleased to announce the poll results of the 2023 first extraordinary general meeting (the “**EGM**”) held at Sky Fortune Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC on Friday, 13 October 2023 at 1:30 p.m.

References are made to the notice of the EGM and the circular of the Company (the “**Circular**”), both dated 14 September 2023. Unless the context otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the date of the EGM, (i) the total number of the issued shares of the Company (the “**Shares**”) was 2,672,528,211 Shares, comprising 2,120,587,711 A Shares and 551,940,500 H Shares; and (ii) holders of 2,672,528,211 Shares (or by authorized proxies) were entitled to attend and vote on the resolution proposed at the EGM. There were no Shares entitling the Shareholders to attend and vote only against the resolution at the EGM.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, no Shareholder was required to abstain from voting at the EGM. No Shareholder has stated in the Circular his/her/its intention to vote against any resolution at the EGM.

ATTENDANCE AT THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

Number of Shareholders and authorized proxies	78
<i>Including:</i> Number of A Shareholders	77
Number of H Shareholders	1
Total number of Shares carrying voting rights (shares)	1,124,330,050
<i>Including:</i> Total number of Shares carrying voting rights held by A Shareholders (shares)	912,516,861
Total number of Shares carrying voting rights held by H Shareholders (shares)	211,813,189
Percentage of the total number of Shares (%)	42.0699
<i>Including:</i> Number of A Shares as a percentage of the total number of Shares (%)	34.1443
Number of H Shares as a percentage of the total number of Shares (%)	7.9256

The EGM was convened in compliance with the requirements of the Company Law and the Articles of Association, and was chaired by Mr. Wu Yifang, the chairman of the Company. Eight (8) Directors of the Company, including four (4) executive Directors, namely Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; One (1) non-executive Director, namely Mr. Yao Fang; and three (3) independent non-executive Directors, namely Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson, attended the EGM.

In compliance with the requirements of the Hong Kong Listing Rules and Article 115 of the Articles of Association, BDO Limited, Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the Shareholder's representatives and members of the supervisory committee of the Company acted as the scrutineers for the vote-counting at the EGM.

POLL RESULTS OF THE RESOLUTION PROPOSED AT THE EGM

The resolution at the EGM was voted by poll. The poll results in respect of the resolution proposed at the EGM were as follows:

ORDINARY RESOLUTION		Number of valid votes		
		For	Against	Abstain
1.	To consider and approve the adjustment to the investment amounts for certain investment projects of the 2022 Non-Public Issuance and addition of new investment sub-projects.	1,124,167,348 (99.9855%)	105,002 (0.0093%)	57,700 (0.0052%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

CERTIFICATION

As certified by and stated in the legal opinion issued by Grandall Law Firm (Shanghai)* (國浩律師(上海)事務所), the Company's PRC legal advisers, the convening and holding of the EGM are in compliance with requirements of the relevant laws, administrative regulations, the Rules of General Meetings of Listed Companies and the Articles of Association, the qualifications of the attendees of the EGM and the convener are legally valid, and the voting procedures and voting results of the EGM are legally valid.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
13 October 2023

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* For identification purposes only